Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Document › Details

Wilex AG. (2/6/17). "Press Release: Wilex AG Secures Financing Commitment from Its Main Shareholder Dievini". Munich.

	Organisation	Wilex AG
	Today	Heidelberg Pharma AG (FSE: HPHA)
	Group	Heidelberg Pharma (Group)
	Organisation 2	Dievini Hopp BioTech Holding GmbH & Co. KG
	Group	HOPP Group (family of Dietmar Hopp)
	Product	Antibody Targeted Amanitin Conjugate (ATAC)
	Product 2	venture capital
	Person	Wimmer, Sylvia (Heidelberg Pharma 202203 Corporate Communciations formerly Wilex 201403 Corporate Communications)
	Person 2	Arnold, Katja (MC Services 201309 CIRO Executive Director before Wilex AG + CAT Consultants)

Disclosure of an inside information according to Article 17 MAR

WILEX AG (ISIN DE000A11QVV0 / WL6 / FSE) today announced that it had secured a further financing commitment from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini). dievini will provide the company up to EUR 10 million. The detailed form of the financing will be decided by the management and supervisory boards of WILEX AG as well as dievini at a later date.

With this additional commitment, the company’s cash reach is secured until the end of the second quarter of 2018.

+++ End of the release +++

About WILEX

WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company. The Company’s research and development work is conducted by its subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the company’s own therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate is a BCMA ATAC for multiple myeloma. WILEX’s clinical assets MESUPRON® and REDECTANE® have been partnered, while RENCAREX® is available for out-licensing and further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at http://www.wilex.com/.

Contact

WILEX AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Email: investors[at]wilex.com
Grillparzerstr. 18, 81675 Munich

IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49-89-210 228-40
Mobile: +49 160 9360 3022
E-Mail: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Record changed: 2023-06-05